Alvb (Immuvera Therapeutics) develops Nebumet, an off‑the‑shelf nebulized immunotherapy derived from the BCG vaccine for dogs with solid tumors and lung metastases. The inhaled formulation targets metastatic sites, improves survival, and generates comparative oncology data to inform human cancer research, while being positioned for veterinary market approval by 2028.
Funding
Funding not disclosed
Founders
Product
Problem
Companion animals with solid tumors often develop lung metastases, for which there are few safe and effective treatment options. Existing therapies are typically invasive, costly, and may not extend survival or preserve quality of life. This limits veterinary oncologists’ ability to manage hard‑to‑treat cancers and hampers data collection that could inform human oncology.
Solution
Alvb (Immuvera Therapeutics) is developing Nebumet, an off‑the‑shelf nebulized immunotherapy based on the well‑established BCG vaccine, specifically formulated for dogs with solid tumors. The product is inhaled directly into the lungs, targeting metastatic sites while activating local immune responses. Preclinical and early clinical data show improved survival times in treated dogs with a favorable safety profile. The company leverages a comparative oncology model, using naturally occurring canine cancers to generate translational insights for human cancer treatment. Nebumet follows a clear regulatory pathway, aiming for veterinary market approval by 2028, and the platform can be expanded to other cancer types and species.
Target Audience
Primary customers are veterinary oncology clinics and veterinary hospitals treating dogs with solid tumors, as well as pet owners seeking advanced cancer care for their animals. Secondary audiences include research institutions and pharmaceutical partners interested in comparative oncology data.
Features
- Nebulized delivery of BCG vaccine enabling direct treatment of lung metastases in dogs
- Off‑the‑shelf formulation with >30 years of human safety data supporting rapid market entry
- Proprietary formulation and multiple patent families protecting the technology through 2045
- Demonstrated survival benefit in early canine studies with maintained quality of life
- Scalable platform technology adaptable to additional solid tumor indications and other companion species
- Integrated data collection framework to support comparative oncology research and human translational studies